Form 8-K Pyxis Oncology, Inc. For: Feb 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Pyxis Oncology appoints Tom Civik as interim CEO
February 6, 2026 4:11 PM ESTPyxis Oncology Inc. (NASDAQ: PYXS) announced a leadership change effective February 2, 2026. Dr. Lara Sullivan ceased serving as Chief Executive Officer and principal executive officer of the company.
The board of directors appointed Tom Civik, a current director, as interim Chief Executive Officer and... More
